Company Profile
Grifols Stock Price, News & Analysis
- Ticker:
- GRFS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.75 USD (+2.24%)
Close
Last updated: July 27, 2026
5.19B USD
Market cap
Why the stock is moving
As of Jul 27, 2026, GRFS closed up 2.24% at $7.75. No new same-company headline was identified in the current news window.
Company overview
Business overview
Grifols is a plasma-therapeutics company with a major business in immunoglobulins, plasma-derived medicines, and diagnostics.
Geographic Base and Sector Classification
Headquartered in Spain and listed in the United States as an ADR, Grifols has a global plasma and diagnostics footprint.
Business Model Characteristics
The company depends on plasma collection, manufacturing execution, and steady demand for specialty biologics.
Position Within the Biotechnology Landscape
Grifols sits in a unique biologics niche where supply chain, pricing, and plasma collection trends matter as much as clinical catalysts.
Future catalysts
Grifols’ catalysts are plasma-collection recovery, debt-reduction execution, and any step that makes the balance-sheet story less distracting. This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile. Better execution here can matter even before a new product or trial headline lands.
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
- 02
- 03
ADMA Biologics Reports First Quarter 2026 Financial Results and Provides Business Update
ADMA · Source: ADMA Biologics
- 04
- 05
ADMA Biologics to Report First Quarter 2026 Financial Results on May 6, 2026
ADMA · Source: ADMA Biologics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Grifols (GRFS)?
Grifols (GRFS) most recently closed at 7.75 USD, a +2.24% move versus the previous session.
What is the market cap of Grifols (GRFS)?
Grifols currently has a market capitalization of 5.19B USD on BioPharmSignal.
What does Grifols do?
Grifols is a plasma-therapeutics company with a major business in immunoglobulins, plasma-derived medicines, and diagnostics.
On which exchange is GRFS stock listed?
Grifols (GRFS) is associated with NASDAQ, United States, Biopharma.
What is Grifols?
Grifols’ catalysts are plasma-collection recovery, debt-reduction execution, and any step that makes the balance-sheet story less distracting.
Which conditions is Grifols targeting with Grifols?
Grifols’ catalysts are plasma-collection recovery, debt-reduction execution, and any step that makes the balance-sheet story less distracting.
How does Grifols describe recent progress with Grifols?
Grifols’ catalysts are plasma-collection recovery, debt-reduction execution, and any step that makes the balance-sheet story less distracting.
What is This?
This matters because it helps show whether the company can turn its current footprint into a cleaner earnings profile.